Pernix Therapeutics Holdings Inc. (Nasdaq: PTX) will acquire the U.S. rights to GlaxoSmithKline's (NYSE: GSK) migraine treatment Treximet. Shares of Pernix leaped $1.22 to $5.50 while GlaxoSmithKline stock slipped 44 cents to $55.08.
Pernix To Acquire Treximet Rights
May 14, 2014 at 12:55 PM EDT
